This knowledge gap served as a driving force for our study, prompting us to investigate the expression of ROBO1 in clinical ovarian cancer samples and to devise a safe and efficient treatment strategy for ovarian cancer patients exhibiting ROBO1 expression. Here, ROBO1 is linked to ovarian carcinoma.